Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Rybrevant 350mg Injection
Manufacturer/Marketed By : JOHNSON & JOHNSON PVT LTD
$905.93 $817.66
Sidmex Inovia offers bulk export supply of Rybrevant 350mg Injection (AMIVANTAMAB) for hospitals, distributors and tender buyers. Request a quote with your quantity and destination country.Documents, cold-chain shipping and tenders:...
AMIVANTAMAB
Active Pharmaceutical Ingredient
Rybrevant 350mg Injection
$905.93
$817.66
Sidmex Inovia offers bulk export supply of Rybrevant 350mg Injection (AMIVANTAMAB) for hospitals, distributors and tender buyers. Request a quote with your quantity and destination country.
Documents, cold-chain shipping and tenders: see our Export FAQ.
Priority markets: United Arab Emirates, Brazil, Turkey, Singapore, Kenya, Somalia, Ghana, Saudi Arabia, Mauritius, Nigeria, Tanzania, Senegal, Democratic Republic of the Congo, Mali. We also export worldwide, including:
Middle East: Oman, Qatar, Kuwait, Bahrain, Iraq, Jordan, Lebanon, Yemen, Iran
Africa: Egypt, Algeria, Morocco, Libya, Burkina Faso, Côte d'Ivoire, Gambia, Rwanda, Ethiopia, Djibouti, South Africa, Zimbabwe
Asia: Sri Lanka, Bangladesh, Nepal, Maldives, Philippines, Vietnam, Laos, Malaysia, Thailand, Taiwan
CIS & Eastern Europe: Russia, Kazakhstan, Uzbekistan, Azerbaijan, Georgia, Serbia, Latvia, Tajikistan
Latin America & Caribbean: Mexico, Chile, Peru, Colombia, Bolivia, Venezuela
Europe & Other: Switzerland, United Kingdom, Canada
Related products we supply: Alburel 20 gm/100 ml Injection
Rybrevant 350mg injection contains the active substance Amivantamab. It is an antineoplastic drug that belongs to the class of medications called bispecific antibodies. It is used to treat a type of cancer called non-small cell lung cancer (NSCLC) that spreads to other parts of the body and has certain changes in a gene called EGFR. It is also used if it cannot be removed by surgery and has worsened during or after treatment with other anticancer medications. Do not take this injection if you are allergic to amivantamab or any other ingredients of this medicine. Inform your physician if you have suffered from inflammation of your lungs or any other lung conditions before initiating the therapy. Report to your physician if you face any symptoms of sudden difficulty in breathing, cough, or fever that may suggest inflammation of the lungs. Rybrevant 350mg injection is not recommended for children or young people below 18 years of age. Inform your physician if you have kidney problems, liver or lung problems before initiating the therapy. The common side effects of Rybrevant 350mg injection are rash, nail inflammation, musculoskeletal pain, shortness of breath, nausea, fatigue, swelling, inflamed and sore mouth, cough, constipation, and vomiting. This medicine may cause harm to the fetus hence use effective contraception during the treatment.
Active Pharmaceutical Ingredient
Uses
• Non-small cell lung cancer (NSCLC)
Benefits
Rybrevant 350mg injection is an epidermal growth factor receptor (EGFR), and mesenchymal-epithelial transition factor (MET) targeted bispecific antibody that has been designed to recognize and attach to specific targets in the body. It targets two proteins found in cancer cells. It works by attaching to these proteins and may help to slow or stop your lung cancer from growing. It may also reduce the size of the tumor.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Most Common Side Effects
• Severe rashes in the skin
• Eye pain and infection
• Inflammation of the lungs
• Infusion reactions
Common Side Effects
• Swelling in the face, hands, and feet
• Inflammation in the nails
• Constipation
• Nausea, vomiting
• Inflamed and sore mouth
• Musculoskeletal pain
• Cough
• Shortness of breath
• Tiredness
How To Use
It will be given to you by a doctor or nurse in a hospital or clinic setting trained in cancer chemotherapy. It is given as an intravenous infusion drip (into your vein) for several hours. Do not self-administer the injection. Your doctor will decide the dose and duration of the treatment based on your disease severity, body weight, and other factors.
Safety Advice
• Breast Feeding: Breastfeeding is not recommended in patients taking Rybrevant 350mg injection because the medicine passes into the breast milk in small amounts and may harm your baby.
• Alcohol: It is unknown whether consuming alcohol is safe during the treatment with Rybrevant 350mg injection. Inform your doctor if you are a chronic drinker.
• Liver: It is unknown whether Rybrevant 350mg injection can be used in patients with liver disorders. Consult your doctor if you have any liver problems before starting the treatment.
• Lungs: It is unknown whether Rybrevant 350mg injection can be used in patients with lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.
• Driving: Rybrevant 350mg injection does not affect the ability to drive. If you feel tired or dizzy after taking this medicine, do not drive and consult your doctor for more advice.
• Pregnancy: Rybrevant 350mg injection is unsafe to administer in pregnant women because it may affect the fetus. Inform your physician if you are pregnant, suspect pregnancy, or planning to become pregnant. Using an effective birth control method during the treatment and for 3 months after your last dose is necessary.
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.